Korean pharma scandal deepens after disclosure in ICC case

A scandal in Korea over the mislabelling of a gene therapy treatment for osteoarthritis has intensified after it emerged in an ICC arbitration that the product’s developer was allegedly aware two years ago that its ingredients had changed.


Get unlimited access to all Global Arbitration Review content